Varenicline Tartrate (Chantix) Tablets

Presentation

Apo-Varenicline 0.5 mg; bottle of 56 tablets (NDC 60505-4765-5)

Apo-Varenicline 1 mg; bottle of 56 tablets (NDC 60505-4766-6)

Apo-Varenicline 0.5 mg and 1 mg; Starter Blister Pack of 53 tablets; (NDC 60505-4767-0)

Apo-Varenicline 1 mg: Continuation Blister Pack of 56 tablets (NDC 60505-4766-5)

Availability and Estimated Shortage Duration

Available

Available

Estimated Date Available; TBD

Estimated Date Available; TBD

Related Information

Apotex Corp., in coordination with the U.S. FDA, has initiated temporary importation of Apo-Varenicline (varenicline tartrate) 0.5 mg and 1 mg tablets into the U.S. market to address a drug shortage of CHANTIX®. The varenicline tartrate tablets marketed in Canada under the name Apo-Varenicline by Apotex Inc. are approved by Health Canada as a generic equivalent to CHAMPIX® tablets manufactured by Pfizer Canada, Inc. CHAMPIX® is the brand name of CHANTIX® sold in Canada. Product is available via Apotex’s authorized distributors. Contact your primary wholesaler/distributor to place orders.

Shortage Reason (per FDASIA)

 

US FDA Link: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Varenicline%20Tartrate%20(Chantix)%20Tablets&st=c&tab=tabs-1